Versant Ventures and Eli Lilly Invest $100 Million in Seawolf Therapeutics to Advance Virus-Free Gene Therapy Delivery
Trendline

Versant Ventures and Eli Lilly Invest $100 Million in Seawolf Therapeutics to Advance Virus-Free Gene Therapy Delivery

What's Happening? Versant Ventures, Eli Lilly, and other investors have collectively invested $100 million into a new startup named Seawolf Therapeutics. The company's primary objective is to address a significant challenge in gene therapy: delivering genes to patients without relying on viruses. Vi
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.